Jun. 30, 2025
WuXi XDC Announces the Mechanical Completion of its Singapore Site, Accelerating the Global Expansion of Bioconjugates Manufacturing
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & Solutions
Services & Solutions - Investor Relations
Investor Relations - News & Resources
News & Resources
Press Releases
-
-
Mar. 20, 2025WuXi XDC Received Multiple Awards from 2025 Extel (previously “Institutional Investor”) Ranking in Diverse Categories -
Apr. 10, 2025WuXi XDC Granted ISO 22301 Certification -
Apr. 03, 2025WuXi XDC and Mabsoft Therapeutics Form Strategic Partnership to Accelerate Development of Next-Generation Immune-Stimulating Antibody Conjugates (ISACs) -
Mar. 24, 2025WuXi XDC Achieved Another Remarkable Year with Extraordinary Business Performance and Financial Results for 2024 -
Mar. 13, 2025WuXi XDC Wins Multiple Awards at Asia-Pacific Biopharma Excellence Awards 2025 -
Mar. 11, 2025WuXi XDC and AbTis Announce Strategic Partnership to Advance Next-Generation ADCs -
Mar. 07, 2025WuXi XDC Accelerates Novel ADC Development with Integrated Technology Platform and End-to-End Services -
Feb. 25, 2025WuXi XDC and LigaChem Biosciences Strengthen Partnership with Expanded MOU to Accelerate ADC Development
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?